zanubrutinib – Talk Bio

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

4 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

1 year ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies

BeiGene Scores Two Major FDA Approvals – Trivimbra for Esophageal Cancer and Brukinsa for Follicular Lymphoma

1 year ago talkbio0Tagged Accelerated Approval, Approved, BeiGene, Brukinsa, Esophageal Neoplasms, Lymphoma, Follicular, obinutuzumab, tislelizumab, Trivimbra, United States Food and Drug Administration, zanubrutinib

BeiGene, Trivimbra (tislelizumab), Esophageal Cancer, Brukinsa (zanubrutinib), Follicular Lymphoma, FDA Approval, Accelerated Approval, Obinutuzumab